Andrea Bileck

University of Vienna — Austria

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index2.4kcitations315works1.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(95), Computational Drug Discovery Methods(44), Cancer, Hypoxia, and Metabolism(28), Immunotherapy and Immune Responses(24), vaccines and immunoinformatics approaches(21)

Publications315 total

Proteomic and morphologic characterization of ovine macrophage differentiation and polarization

Scientific Reports·2025Open Access

Suppl. Figure S3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S10 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl Figure S4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S13 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S12 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S14 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S15 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl Figure S11 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl.Figure S16 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

page 1 of 16Next →

Frequent Co-authors

Christopher Gerner(45), Samuel M. Meier(14), Astrid Slany(13), Dominique Kreutz(10), Lukas Janker(10), Besnik Muqaku(7), Laura Niederstaetter(6), Rupert L. Mayer(6), Julia Brunmair(5), Verena Paulitschke(5), Thomas Mohr(5), Giorgia Del Favero(5), Johanna C. Mader(4), Sabine Taschner‐Mandl(4), Fikret Rifatbegovic(4), Gerhard Hagn(4), Marlene C. Gerner(4), Klaus G. Schmetterer(4), Benjamin Neuditschko(4), Patricia Bortel(4)